Clinical trial · no report yet · Phase 3

KEYNOTE-992

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

NCT04241185 ↗
Active, not recruiting
Merck Sharp & Dohme LLC
Deep

We haven't built an HCP commentary report on KEYNOTE-992 (pembrolizumab, cisplatin and 3 more in Urinary Bladder Neoplasms) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on KEYNOTE-992 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Channel	Indexed
YouTube	8
X threads	8
Podcasts	6

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)
Phase: Phase 3
Status: Active, not recruiting
Conditions: Urinary Bladder Neoplasms
Interventions: Pembrolizumab; Conventional Radiotherapy (Bladder only); Conventional Radiotherapy (Bladder and pelvic nodes); Hypofractionated Radiotherapy (Bladder only); Cisplatin; Fluorouracil (5-FU); Mitomycin C (MMC); Gemcitabine; Placebo to Pembrolizumab
Arms: Pembrolizumab + Chemotherapy + Radiotherapy · Experimental
Placebo + Chemotherapy + Radiotherapy · Placebo comparator
Enrollment: 520 (estimated)
Primary outcomes: Bladder Intact Event-Free Survival (BI-EFS)
Sponsor: Merck Sharp & Dohme LLC
Start: May 19, 2020
Primary completion: Jan 31, 2027 (estimated)
Results posted: No
Registry record: NCT04241185 · updated May 1, 2026